Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia.
about
Promising and delivering gene therapies for vision lossCanine CNGA3 Gene Mutations Provide Novel Insights into Human Achromatopsia-Associated Channelopathies and TreatmentGene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 AchromatopsiaA Naturally Occurring Canine Model of Autosomal Recessive Congenital Stationary Night BlindnessLoss of retinitis pigmentosa 2 (RP2) protein affects cone photoreceptor sensory cilium elongation in miceAssessment of Rod, Cone, and Intrinsically Photosensitive Retinal Ganglion Cell Contributions to the Canine Chromatic Pupillary ResponseCNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone functionSuccessful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.Five novel CNGB3 gene mutations in Polish patients with achromatopsiaExtended duration of transgene expression from pegylated POD nanoparticles enables attenuation of photoreceptor degeneration.A cyclic nucleotide-gated channel mutation associated with canine daylight blindness provides insight into a role for the S2 segment tri-Asp motif in channel biogenesis.Intravitreal Ciliary Neurotrophic Factor Transiently Improves Cone-Mediated Function in a CNGB3-/- Mouse Model of Achromatopsia.Achromatopsia caused by novel missense mutations in the CNGA3 gene.AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term EffectsLet There Be Light: Gene and Cell Therapy for Blindness.Advances in Gene Therapy for Diseases of the Eye.Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosaAdvances in gene therapy technologies to treat retinitis pigmentosa.Immuno-histochemical analysis of rod and cone reaction to RPE65 deficiency in the inferior and superior canine retina.Providing comprehensive genetic-based ophthalmic care.Gene replacement therapy for retinal CNG channelopathies.Gene therapies for inherited retinal disorders.Dog models for blinding inherited retinal dystrophiesVibratome sectioning mouse retina to prepare photoreceptor cultures.Gene therapy for achromatopsia.The inositol metabolism pathway as a target for neuroprotective strategies.Concepts and Strategies in Retinal Gene Therapy.Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-Mutant Dogs.Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options.Neuroprotective strategies for retinal disease.Retinal Cyclic Nucleotide-Gated Channels: From Pathophysiology to Therapy.BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure.Gene Therapy for Color Blindness.
P2860
Q27007079-31031462-3917-4299-B4AC-921402B43950Q27316578-3C644EDF-2253-422A-B8A7-A2B70D0DA832Q27318262-575223BA-C08E-47D6-B1CA-6FB275D5243FQ27320207-CF595CAD-5F2B-4024-BB3E-96FD1A373F1AQ28267539-2259B740-C6E4-4395-9328-93B08E506886Q30834824-197AC314-58DC-4138-ABC0-1403ED61F27AQ34312144-B9663D04-10B9-42E0-820E-8CA4366DC17AQ34497784-4AFEBF0E-D549-459D-957D-1C5C5C408240Q34787667-EE9B41B8-92FC-4C04-8837-42F4D1782199Q35054149-E53DFAC5-6CE6-4705-8BB2-3E5C54AC57F3Q35106274-E4B91B35-0E18-4B81-B9F0-2C070A5DDE7FQ36232212-346983D7-8BB9-4FE8-90BC-6A773A57BDA3Q36243094-299D0399-CA8A-448E-BF8A-412237E8DA60Q36396453-9248D88C-F335-44C9-A437-8A9B857B5C1AQ36654534-4BF1D259-195B-4582-BD17-A1CB3110B470Q37190609-401E154B-045D-4329-9A37-2FB920C8BE89Q37406449-AD39673F-F5A8-4FC0-827B-FC844394006AQ37427526-D48DD0F6-D6C5-4012-BC60-4846FC8ADF8BQ37500297-85085619-8EC4-40D4-8ABE-9114F3DF2486Q38105597-25C29B6F-37D6-47FF-8B4C-DF9BEA9A761EQ38122108-A186C1F3-258E-46F3-9064-A767387E2B2CQ38221905-34EB1494-633C-4132-ADDB-E66764CC7FBCQ38351811-B0138E26-6F39-4995-BA8D-CE20C914E783Q38949176-98269ABB-EA49-40B6-B25A-E17240CE6F56Q39016569-EEDCC2BB-59A9-46CC-997D-5CD33B69D476Q41779887-E8DA7719-3245-45AE-87E1-7BBEE992E46EQ42574125-3ECA558C-4958-487F-961E-7ADEA6473A6DQ45873049-2A46B4ED-43D8-4317-B256-8D144796AB04Q47750345-A1200604-396F-4CF0-9253-40F5A190CCC5Q52372755-E0341711-7775-434F-ACBE-A6E0AA3441E7Q52666370-3C035A2C-3A85-4B33-B3EB-67632C622FB3Q52728747-FF40051A-C2C5-4B33-8279-77DD085A6F31Q52743745-A40B3205-0B60-49B4-AF3E-083AB305C535
P2860
Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Transient photoreceptor decons ...... ate stage CNGB3-achromatopsia.
@en
type
label
Transient photoreceptor decons ...... ate stage CNGB3-achromatopsia.
@en
prefLabel
Transient photoreceptor decons ...... ate stage CNGB3-achromatopsia.
@en
P2093
P2860
P356
P1433
P1476
Transient photoreceptor decons ...... ate stage CNGB3-achromatopsia.
@en
P2093
Amaliris Gonzalez
Amanda T Parton Corr
András M Komáromy
Ann E Cooper
Britt Levy
Gustavo D Aguirre
Jessica S Rowlan
Sanford L Boye
Shelby L Reinstein
P2860
P304
P356
10.1038/MT.2013.50
P577
2013-04-09T00:00:00Z